| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-09-04 | Vectura (UK) Novartis (Switzerland) Pfizer (USA -NY) | Ultibro® Breezhaler® (indacaterol / glycopyrronium bromide), Seebri® Breezhaler®(glycopyrronium bromide) | maintenance treatment of chronic obstructive pulmonary disease (COPD) | Inflammatory diseases - Respiratory diseases | Commercialisation agreement | |
| 2014-09-03 | Abbvie (USA - IL) Calico (USA - CA) | age-related diseases, including for neurodegeneration and cancer | R&D |
Cancer - Oncology - Neurodegenerative diseases | R&D agreement | |
| 2014-09-03 | AstraZeneca (UK) Redx Pharma (UK) | new molecules targeting a genetic driver of tumour growth and survival | R&D collaboration |
Cancer - Oncology | R&D agreement | |
| 2014-09-03 | Gedeon Richter (Hungary) Palatin Technologies (USA - NJ) | bremelanotide | female sexual dysfunction (FSD) | Women health | Licensing agreement | |
| 2014-09-03 | CMC Biologics (Denmark) Zymeworks (Canada) | recombinant human IgG1 bispecific antibody | Cancer - Oncology | Production agreement | ||
| 2014-09-03 | Cerenis Therapeutics (France) | Nomination | ||||
| 2014-09-03 | Abbvie (USA - IL) Infinity Pharmaceuticals (USA - MA) | duvelisib (IPI-145) | blood cancers, including indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL) | Cancer - Oncology | Development agreement | |
| 2014-09-03 | Roche (Switzerland) Infinity Pharmaceuticals (USA - MA) | Gazyva® (obinutuzumab) and duvelisib (IPI-145) | blood cancers | Cancer - Oncology | Clinical research agreement | |
| 2014-09-03 | Kiadis Pharma (The Netherlands) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2014-09-03 | Bind Therapeutics (USA - MA) | member of the board of directors | nomination | Cancer - Oncology | Nomination | |
| 2014-09-02 | Diamyd Medical (Sweden) University of California in Los Angeles (UCLA) (USA - CA) | patent portfolio for the therapeutic use of GABA (gamma-aminobutyric acid) | type 1 diabetes, type 2 diabetes, metabolic syndrome, rheumatoid arthritis | licensing | Metabolic diseases - Inflammatory diseases - Autoimmune diseases - Rheumatic diseases | Licensing agreement |
| 2014-09-02 | Allergopharma, the Merck Business Unit Allergy (Germany) S-TARget therapeutics (Austria) | S-TIR™ technology | Allergic diseases - Immunological diseases | Licensing agreement | ||
| 2014-09-02 | Chiesi Farmaceutici (Italy) A. M. Pappas & Associates (USA - NC) | Chiesi Ventures | Rare diseases | Collaboration agreement | ||
| 2014-09-02 | EMD Serono Research and Development Institute, Inc., a subsidiary of Merck KGaA, (Germany) Massachusetts General Hospital (USA - MA) | therapeutic targets, pathogenic immune cell types and biomarkers | systemic lupus erythematosus, lupus nephritis | Autoimmune diseases | Collaboration agreement | |
| 2014-09-02 | Integragen (France) the French Intergroup for Thoracic Oncology (IFCT) (France) | miR-31-3p biomarker | advanced stage non-small cell lung cancer (NSCLC) | collaboration R&D |
Cancer - Oncology | Collaboration agreement |
| 2014-09-02 | Epizyme (USA - CO) | Cancer - Oncology | Nomination | |||
| 2014-09-02 | CleveXel Pharma (France) Guilin Pharmaceutical (China) | anti-malarial products | malaria | development |
Infectious diseases | Development agreement |
| 2014-09-01 | Ablynx (Belgium) Eddingpharm (China) | ozoralizumab (ATN-103) | rheumatoid arthritis and other indications | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | Licensing agreement | |
| 2014-09-01 | Tigenix (Belgium) | Autoimmune diseases – Inflammatory diseases | Nomination | |||
| 2014-09-01 | Tigenix (Belgium) | Autoimmune diseases – Inflammatory diseases | Nomination |
